University of Miami
Welcome,         Profile    Billing    Logout  
 122 Trials 
105 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rugo, Hope
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NCT03562637 / 2018-001438-16: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Recruiting
3
668
Europe, US, RoW
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
OBI Pharma, Inc, OBI Pharma, Inc.
Triple Negative Breast Cancer
12/25
12/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Recruiting
2
30
US
Talazoparib, Talzenna
Massachusetts General Hospital, Pfizer
Breast Cancer
07/25
12/25
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 044, NCT03095352: Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Completed
2
70
US
Pembrolizumab, Carboplatin, Ribocarbo, Trastuzumab
Hope Rugo, MD, Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Breast Cancer, Chest Wall Disease
11/24
11/24
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
ENCORE, NCT06774027: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Not yet recruiting
N/A
100
US
Specimen collection, Biospecimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Non-Investigational ADC, Medical Record Review, Medical Chart Review
University of California, San Francisco, Translational Breast Cancer Research Consortium, Gilead Sciences, Johns Hopkins University
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
12/30
12/30
Martinez, Jaime
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
Merchan, Jaime
STEALTH-001, NCT06444815: A Study of VET3-TGI in Patients With Solid Tumors

Recruiting
1
60
US
VET3-TGI, Pembrolizumab
KaliVir Immunotherapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
09/27
12/27
MAST, NCT05346484: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

Recruiting
1
100
US, RoW
CF33-hNIS, VAXINIA, HOV2, Pembrolizumab, KEYTRUDA®
Imugene Limited
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
12/24
01/25
Gonzalgo, Mark
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
NCT03171493: Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

Completed
1
8
US
MV-NIS
Vyriad, Inc., Mayo Clinic
Urothelial Carcinoma
02/21
05/23
Lutzky, Jose
CA224-094, NCT04552223: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Active, not recruiting
2
27
US
Nivolumab, Opdivo, Relatlimab, BMS-986016
Jose Lutzky, MD, Bristol-Myers Squibb, United States Department of Defense
Metastatic Uveal Melanoma
01/24
01/26
NCT04291105: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
12/24
03/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
225
Europe, US
TNG462, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1
438
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
01/27
11/27
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
100
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Chung, Vincent
IMM6415-101, NCT06208124: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Recruiting
1/2
240
US
IMM-6-415
Immuneering Corporation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
06/27
07/27
NCT05023486: NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
140
US
NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy
Novita Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumor Malignancies
09/25
09/25
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Hourglass Nov 2024 - Dec 2024 : Initial data from at least one additional arm of the Phase 2a portion
Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruiting
1/2
158
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
AMPLIFY-201, NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Active, not recruiting
1
25
US
ELI-002 2P
Elicio Therapeutics
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
01/23
03/26
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26
Lopes, Gilberto
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
CDR404-001, NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Recruiting
1
42
Europe, US
CDR404
CDR-Life AG
Select Advanced Solid Tumors
06/26
12/27
NCT06561685: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1
160
Japan, US
LY4050784
Eli Lilly and Company, Loxo Oncology, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
10/27
10/27
Hoffer, Michael E
NCT04107610: Normative Oculomotor and Vestibular Data in Pediatric Population

Not yet recruiting
N/A
600
US
I-PAS
Neurolign, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), University of Miami
Healthy
01/22
08/22
NCT04087044: Computerized Rotational Head Impulse Test-Vertical (crHIT-vertical)

Active, not recruiting
N/A
186
US
Computerized Rotational Head Impulse Test ( crHIT)-Vertical, crHIT Vertical
Neurolign, University of Miami, University of Pittsburgh, Mayo Clinic
Vestibular Function Tests
05/22
08/22
NCT03539848: Diagnosis of mTBI in a Community Setting

Recruiting
N/A
400
US
I-PAS Goggles
University of Miami, Neurolign
Traumatic Brain Injury, Mild Traumatic Brain Injury, Brain Injuries, Brain Injuries, Traumatic, Head Injury
09/26
09/26
NCT06375278: Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation

Recruiting
N/A
54
US
Intra-Ear Canal Cooling Catheter
Restorear Devices LLC, University of Miami, National Institute on Deafness and Other Communication Disorders (NIDCD)
Cochlear Implants, Cochlear Implantation, Hearing Loss
04/26
07/26
NCT06729632: Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss

Recruiting
N/A
116
US
Cold pack-delivered mild therapeutic hypothermia
Restorear Devices LLC, University of Miami, National Institute on Deafness and Other Communication Disorders (NIDCD)
Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia, Cooling, Occupational Exposure, Occupational Health, Hidden Hearing Loss
06/26
12/26
Lee, David M
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
ABCI, NCT05802264: Study to Assess Amphotericin B Cystetic for Inhalation () Doses in Healthy Volunteers & People With Cystic Fibrosis

Recruiting
1
84
RoW
ABCI, Amphotericin B Cystetic for Inhalation, Placebo
Cystetic Medicines, Inc., DevPro Biopharma
Cystic Fibrosis
12/24
12/24
NCT04311086: SPYRAL DYSTAL Renal Denervation Global Clinical Study

Completed
N/A
128
Europe, US
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases
12/22
12/22
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Active, not recruiting
N/A
450
Europe, Canada, US
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Occlutech International AB
Stroke, Patent Foramen Ovale, PFO
11/25
10/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
OLP-II, NCT05940857: US National OCS Liver Perfusion (OLP) Registry

Recruiting
N/A
100000
US
OCS Liver
TransMedics
Liver Transplant
10/31
10/31
Kim, Joo Sung
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting
2
40
US, RoW
ABN401
Abion Inc
Advanced Solid Tumors
04/25
08/25
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Recruiting
N/A
9
RoW
ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell
Anterogen Co., Ltd.
Crohn Disease
12/26
12/26
Loebe, Matthias
COMPETENCE, NCT01187368: Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System

Suspended
N/A
399
US
EVAHEART Left Ventricular Assist System (LVAS), EVA2, HeartMate 3, HM3
Evaheart, Inc.
Heart Failure
07/27
07/28
Cook, Robert L
NCT05090267: The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study

Recruiting
N/A
80
US
Probiotic Supplement, Transcutaneous Vagal Nerve Stimulation (tVNS)
University of Florida, University of Miami, University of Louisville, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Exegi Pharma, LLC, Soterix Medical
Cognition, Gut Microbiome
06/26
06/26
Espinoza, Luis
TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Recruiting
3
480
US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Diabetes Type 2
06/26
07/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Escobar, Mauricio
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
Starke, Robert M
VANTAGE, NCT04391803: EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms with the Pipeline™ Flex Embolization Device with Shield TEchnology™ (ELEVATE)

Recruiting
N/A
200
NA
Pipeline™ Flex Embolization Device with Shield Technology™, Pipeline™ Shield Device
Medtronic Neurovascular Clinical Affairs
Intracranial Aneurysm, Ruptured Aneurysm
01/26
01/27
NCT04129125: The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

Completed
N/A
328
US
Zoom Reperfusion System
Imperative Care, Inc.
Ischemic Stroke, Acute Stroke
05/24
05/24
EMBOLISE, NCT04402632: Embolization of the Middle Meningeal Artery with ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma

Active, not recruiting
N/A
600
US
Surgical Management, Surgical Management + Treatment, No Treatment, Treatment
Medtronic Neurovascular Clinical Affairs
Subdural Hematoma
12/24
03/25
NCT04057352: Citadel Embolization Device Study

Recruiting
N/A
150
US
Citadel Embolization Device
Stryker Neurovascular
Unruptured Wide-neck Aneurysms
06/26
06/26
Ehrenreich-May, Jill
CBToolkit, NCT06213142: Developing the Unified Protocol-Single Session Experience Platform for Adolescent Mental Health

Completed
N/A
57
US
CBToolkit
3-C Institute for Social Development, University of Miami, Stony Brook University
Depression, Depression, Anxiety, Depression in Adolescence, Anxiety
08/23
08/23
Adler, Eric D
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure

Recruiting
2
150
US
AB-1002, Gene Therapy, NAN-101
Asklepios Biopharmaceutical, Inc.
Congestive Heart Failure
10/26
12/30
NCT03766386: The Natural History of Danon Disease

Recruiting
N/A
200
US
University of California, San Diego, Rocket Pharmaceuticals Inc.
Danon Disease
11/24
11/24
Porges, Eric
NCT05090267: The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study

Recruiting
N/A
80
US
Probiotic Supplement, Transcutaneous Vagal Nerve Stimulation (tVNS)
University of Florida, University of Miami, University of Louisville, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Exegi Pharma, LLC, Soterix Medical
Cognition, Gut Microbiome
06/26
06/26
Holcomb, Meredith A
NCT04721327: Remote Care: The Future of Cochlear Implants

Completed
N/A
30
US
remote CI programming
University of Miami, Cochlear
Cochlear Implants
06/23
06/23
ACE, NCT06293482: Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population

Recruiting
N/A
50
US
Cochlear™ Nucleus® System
Cochlear, NAMSA, LWB Consulting, Althea Anagnostopoulos Harrington, MV Clinical Research, LLC
Hearing Loss, Sensorineural, Hearing Loss, Bilateral
12/25
06/28
Marchena, Eduardo de
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
Yavagal, Dileep R
NCT03915431: A Study of NCS-01 in Patients With Acute Ischemic Stroke

Active, not recruiting
1/2
16
US
NCS-01
NC Medial Research Inc
Ischemic Stroke
10/27
10/28
GRASSROOT, NCT06249776: Gravity Stent-Retriever System for Reperfusion of Large Vessel Occlusion Stroke Trial

Recruiting
N/A
100
RoW
Supernova revascularization device
Gravity Medical Technology, INC
Ischemic Stroke, Stroke, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Vascular Diseases, Cardiovascular Diseases
03/26
12/26
Rocha, Monica
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
UCLA B-13, NCT05319873: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Recruiting
1/2
18
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Ribociclib, Kisqali, LEE-011, LEE011, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Tucatinib, ARRY-380, Irbinitinib, ONT-380, Tukysa
Jonsson Comprehensive Cancer Center, Seagen Inc., Novartis
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
04/25
04/26
Ma, Pearl
FLOWS, NCT06454916: Functional Lumen Opening With Self-Forming Magnetic Anastomosis

Recruiting
N/A
70
US
Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc
GI Windows, Inc.
Small Bowel Anastomosis
06/25
08/25
Online
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Active, not recruiting
2
320
NA
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
KEYNOTE-051, NCT02332668 / 2014-002950-38: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/)

Checkmark Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Dec 2019 - Dec 2019: Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Recruiting
1/2
370
Europe, US, RoW
Pembrolizumab, MK-3475
Merck Sharp & Dohme LLC
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
10/27
10/27
Cieslicki, Anabela
RISE 2, NCT06132893: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting
2/3
390
Europe, US, RoW
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Focal Epilepsy
08/25
09/25
Govind, Varan
NCT05090267: The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study

Recruiting
N/A
80
US
Probiotic Supplement, Transcutaneous Vagal Nerve Stimulation (tVNS)
University of Florida, University of Miami, University of Louisville, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Exegi Pharma, LLC, Soterix Medical
Cognition, Gut Microbiome
06/26
06/26
Ortega, Milton
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
Kim, Joosung
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Recruiting
N/A
9
RoW
ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell
Anterogen Co., Ltd.
Crohn Disease
12/26
12/26
Shultz, Mitchell
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
NCT05456425: A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Recruiting
3
600
US, RoW
CBT-001, Vehicle
Cloudbreak Therapeutics, LLC
Pterygium
12/25
12/26
Ersa, NCT05454956: Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Completed
2
40
US
TP-03, TP-03 Vehicle
Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
05/23
05/23
Rhea, NCT06054217: Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Active, not recruiting
2
36
US
Vehicle of TP-03, Exploratory Vehicle
Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
06/24
06/24
NCT06264232: AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

Recruiting
N/A
286
US
Cataract Surgery
Carl Zeiss Meditec, Inc., ORA, Inc.
Cataract Senile
12/25
05/26
 

Download Options